2 DENGVAXIA RESPONDENTS NAMED TO DOH POSTS

2 DENGVAXIA RESPONDENTS NAMED TO DOH POSTS

October 27, 2022 @ 5:49 PM 1 month ago


PRESIDENT Ferdinand ‘Bongbong’ Marcos Jr. had been apparently misled when he signed the appointment of two doctors to Department of Health posts despite the duo’s questionable qualifications since they obviously were co-respondents in the string of criminal cases filed against them in connection with the over 150 schoolchildren’s death linked to the anti-dengue Dengvaxia vaccine.

Dr. Maria Lourdes Caballero-Santiago and Dr. Maria Joyce Udtuhan-Ducusin, who may be close to their co-accused, the principal accused actually former DoH secretary and now Iloilo Rep. Janette Garin, were named Director IV and Director III, respectively, as per document from Malacanang and addressed to acting DoH Secretary Maria Rosario Vergeire.

Ducusin was the co-accused in some 156 Dengvaxia cases filed by the families and relatives of the ‘Dengvaxia’ victims while Santiago was co-accused in 152 criminal cases.

The same sources believed that the President was fully unaware about the involvement of the two physicians to Dengvaxia cases.

“For sure, if the President was well informed about them or the two doctors did not keep the information about their involvement in Dengvaxia case, he wouldn’t sign their appointment,” the sources said.

The Public Attorney’s Office filed several civil cases against the respondents led by Garin and former Health Secretary Francisco Duque 3rd while the Department of Justice filed criminal charges against them.

They were specifically reckless imprudence resulting to multiple homicide, violation of the Anti-Torture Law (Republic Act 9745), violation of the Consumer Act of the Philippines (RA 7394) and violation of the Philippine Pharmacy Act (RA 10918).

The DoH, through the Philippine Children’s Medical Center, spent P3-billion to P3.5-billion for a mass vaccination of schoolchildren that began in 2016 against dengue.

Vaccine manufacturer Sanofi Pasteur said in 2017: “The analysis confirmed that Dengvaxia provides persistent protective benefit against dengue fever in those who had prior infection. For those not previously infected by dengue virus, however, the analysis found that in the longer term, more cases of severe disease could occur following vaccination upon a subsequent dengue infection.”